Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...
Finally An Attractive Entry Point Into Novo Nordisk
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
New Hampshire Union Leader1d
U.S. targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
FierceBiotech10d
Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes
Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...
LVMH overtakes Novo Nordisk as Europe’s most valuable company
Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...
Morningstar11d
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
The companies say they'll work to discover and develop treatments for obesity, type 2 diabetes, and cardiovascular disease. Novo Nordisk shares (DK:NOVO.B) (NVO) pared some of their gains in ...
East Idaho News on MSN1d
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
GEN10d
Novo Nordisk, Valo Health Ink Expanded Up-to-$4.6B AI Collaboration
Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...